Anglo-American life sciences VC Abingworth has appointed David Mayer as a partner. He will be based at the company’s offices in Waltham, MA, USA and his prime responsibility will be to support Abingworth’s efforts in growth equity, which will include expansion and acquisition financings, small buyouts and build-ups in healthcare and life science companies.
Abingworth plans to invest between £10m and £40m in each of its growth equity investments.
Mayer has more than 12 years’ experience in growth equity/buyouts, of which eight years have been spent focused on the healthcare sector. He was most recently a managing partner at Thoma Cressey Equity Partners (TCEP). He was one of five managing partners at TCEP, which managed more than US$1.75bn in capital, and he opened their Boston office in 2004. He was also responsible for expanding the areas within healthcare in which the firm now invests to include pharmaceuticals and medical products, in addition to healthcare services.